Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119675 | 0.94 | MEN1 (0.52) | MEN1KMT2ARAF1ATMMCHR1 | |
| SCHEMBL4119609 | 0.89 | MEN1 (0.53) | MEN1KMT2AMCHR1CCR3KDM4E | |
| SCHEMBL4123918 | 0.88 | MEN1 (0.57) | MEN1KMT2AMCHR1CCR3LMNA | |
| SCHEMBL4106129 | 0.88 | CNR1 (0.57) | MEN1KMT2AMCHR1LMNACNR1 | |
| SCHEMBL4112186 | 0.86 | MEN1 (0.60) | MEN1KMT2ARAF1MCHR1CNR1 | |
| SCHEMBL4107568 | 0.86 | MCHR1 (0.58) | MEN1KMT2AMCHR1CCR3BMP1 | |
| SCHEMBL4114155 | 0.85 | MEN1 (0.49) | MEN1KMT2ARAF1MCHR1CCR3 | |
| SCHEMBL4116418 | 0.84 | MEN1 (0.52) | MEN1KMT2AATMMCHR1FPR2 | |
| SCHEMBL4125793 | 0.83 | EPHX2 (0.53) | HSD17B10CCR3KDM4EALDH1A1LMNA | |
| SCHEMBL4107298 | 0.82 | MEN1 (0.55) | MEN1KMT2AATMMCHR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | MEN1 4167/4885KMT2A 2720/4885HSD17B10 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.